Uae Pharmaceutical Monopoly Reform: UAE announces new pharmaceutical rule to break medicine monopolies and lower drug costs | World News – The Times of India

UAE enhances drug security with competition-driven pharmaceutical distribution reform / Image: file

Finding essential medication just got easier, and likely more affordable, for UAE residents. On Tuesday, February 24, 2026, the Emirates Drug Establishment (EDE) activated a historic mechanism designed to dismantle the long-standing “single-agent” monopoly over medical products.For decades, exclusive distributors controlled many life-saving drugs, but that era is ending. This new rule directly responds to strategic priorities aimed at securing the nation’s pharmaceutical supply while making healthcare more competitive and patient-centered.

UAE’s new medical protocols for 2026

The United Arab Emirates has introduced a first-of-its-kind rule aimed at breaking monopolies in the pharmaceutical sector and strengthening medicine availability nationwide. Announced by the Emirates Drug Establishment (EDE), the new framework requires drugmakers to register multiple authorised agents for each medicine they market in the UAE, a departure from the previous single-agent model that often limited supply options. This change is part of the Federal Decree-Law No. (38) of 2024 Governing Medical Products, Pharmacists and Pharmaceutical Establishments, designed to improve the resilience and competitiveness of the healthcare sector.Under the old model, a single distributor handled imports, distribution and supply of a medicine type. This could sometimes slow delivery, reduce flexibility in response to sudden demand spikes or supply chain disruptions, and create conditions for monopolistic control. The new rule is expected to mitigate these risks by broadening choice and competition among authorised agents.

What does the new mechanism mean?

The reform’s core goal is to ensure the continuous availability of medical products across all emirates. By authorizing more than one agent per product, the UAE aims to make it easier for pharmacies, hospitals and patients to access a wider range of medicines without delays. Officials say this will enhance supply chain flexibility, allowing faster responses when demand rises suddenly, such as during public health emergencies, and reducing the chance of shortages. The mechanism also aims to boost distribution efficiency across the UAE by improving inventory management and speeding delivery times. This means that if one supplier faces operational, logistical or unexpected challenges, others can step in to keep supply lines steady. Enhancing distribution networks is expected to benefit healthcare providers and patients alike, especially in remote or high-demand areas.

Encouraging competition UAE’s pharmaceuticals

Officials from the EDE have linked the reform to broader economic and investment strategies. By opening the market to multiple authorised agents per product, the UAE is encouraging fair competition and diversity in distribution channels. This is seen as attractive for international pharmaceutical companies looking to invest or expand their footprint in the Middle East.According to Saeed bin Mubarak Al Hajeri, Minister of State and Chairman of EDE’s Board, the move aligns with national priorities to strengthen pharmaceutical infrastructure, enhance regulatory efficiency and support a robust healthcare ecosystem. He emphasised that pharmaceutical investment is one of the UAE’s economic strengths, and modernising the market framework boosts the country’s global competitiveness.

Improving market stability

Fatima Al Kaabi, Director General of the Emirates Drug Establishment, highlighted that beyond supply continuity, the reform will support market stability and sustainability by aligning local practices with international best standards. She noted that the UAE is well positioned to attract more pharmaceutical industries, drive research and development, and strengthen its role as a regional hub for medicine manufacturing and innovation.The EDE’s broader strategic efforts also focus on enhancing storage, quality control, transportation standards and regulatory oversight, all aimed at preparing the healthcare sector to respond better to both routine demand and extraordinary health challenges.